Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
15.01
-0.07 (-0.46%)
Jun 20, 2025, 4:00 PM - Market closed
Spyre Therapeutics Employees
Spyre Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 35 or 116.67% compared to the previous year.
Employees
65
Change (1Y)
35
Growth (1Y)
116.67%
Revenue / Employee
n/a
Profits / Employee
-$2,449,785
Market Cap
905.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SYRE News
- 4 days ago - Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward - Seeking Alpha
- 5 days ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PRNewsWire
- 6 days ago - Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 - PRNewsWire
- 16 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 25 days ago - Spyre Therapeutics to Participate in Upcoming June Investor Conferences - PRNewsWire
- 6 weeks ago - Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 6 weeks ago - Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PRNewsWire
- 3 months ago - Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PRNewsWire